On July 4, 2017, BIOCAD, a Russia biotechnology company, announced that in August 2017, it expects to receive permanent market authorization in India for Acellbia, its rituximab biosimilar.  BIOCAD reports that its first shipment of Acellbia to India is scheduled for September 2017.  As we previously reported, BIOCAD has also obtained marketing authorization for its rituximab biosimilar in Bolivia and Honduras, under the trade name USMAL.

BIOCAD also reported that in the first quarter of 2018, it expects to receive marketing authorization in India for Herticad, its trastuzumab biosimilar, which is already supplied to Syria, Sri Lanka, and other countries.